|
카테고리
|
Cytokines & Growth Factor
|
|
CAT.NO
|
LGP-12-023
|
|
PRODUCT
|
IL-36β(153aa), Mouse (Murine Interleukin-36 beta, 153aa)
|
|
SIZE
|
10ug, 100ug, 250ug
|
|
PRICE
|
KRW 285,000, 1,522,000, 2,622,000
|
Technical Parameters
| Synonyms |
FIL1 eta, IL-1 eta, IL-1F8, IL-1H2 |
| Accession |
Q9D6Z6 |
| GeneID |
69677 |
| Source |
Escherichia coli. |
| Molecular Weight |
Approximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids. |
| Quantity |
10µg/100µg/250µg |
| AA Sequence |
SSQSPRNYRV HDSQQMVWVL TGNTLTAVPA SNNVKPVILS LIACRDTEFQ DVKKGNLVFL GIKNRNLCFC CVEMEGKPTL QLKEVDIMNL YKERKAQKAF LFYHGIEGST SVFQSVLYPG WFIATSSIER QTIILTHQRG KLVNTNFYIE SEK |
| Purity |
> 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg. |
| Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, 5% trehalose. |
| Endotoxin |
Less than 1 EU/µg of rMuIL-36β, 153a.a. as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Usage |
This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. |
| SDS-PAGE |
 |
| Reference |
1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.
2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.
3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80.
4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6.
5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22. |
| Background |
Interleukin-36 is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. IL-36 beta has two isoforms. IL-36β2 contains one potential N-linked glycosylation site in its C-terminus, while IL -36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Within the IL-1 family, IL-36β/IL-1F8 shares 30 %, 32 %, 37 %, 46 %, 34 %, 45 % and 28 % a.a. sequence identity with IL-1 ra, IL-1β, IL-36Ra/IL-1F5, IL-36α/IL-1F6, IL-37/IL-1F7, IL-36γ/IL-1F9 and IL-1F10, respectively. |
|
|
첨부파일
|
|
|
|
|
|
